Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir

(2012) Grace A. McComsey et al.   AIDS

Body composition changes after switching from protease inhibitors to raltegravir

(2011) Adrian Curran et al.   AIDS

Molecular mechanisms for insulin resistance in treated HIV-infection

(2011) Paul W. Hruz   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

(2011) Jürgen K. Rockstroh et al.   CLINICAL INFECTIOUS DISEASES

Progression of Carotid Intima-Media Thickness in a Contemporary Human Immunodeficiency Virus Cohort

(2011) J. V. Baker et al.   CLINICAL INFECTIOUS DISEASES

Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults

(2010) Katherine Samaras et al.   AIDS

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

(2010) Allison Martin et al.   AIDS

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

(2010) Esteban Martínez et al.   AIDS

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

(2010) Esteban Martinez et al.   AIDS

Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus–Infected PatientsA Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4Antiretroviral Drugs, Risk of MI, and HIV

(2010) Sylvie Lang   ARCHIVES OF INTERNAL MEDICINE

Changes in Inflammatory and Coagulation Biomarkers: A Randomized Comparison of Immediate versus Deferred Antiretroviral Therapy in Patients With HIV Infection

(2010) Jason V Baker et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection

(2010) Jacqueline Neuhaus et al.   JOURNAL OF INFECTIOUS DISEASES

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

(2010) Joseph J Eron et al.   LANCET

Biomarkers and HIV-associated cardiovascular disease

(2010) Jason V Baker et al.   Current Opinion in HIV and AIDS

Association of antiretroviral therapy with fibrinogen levels in HIV-infection

(2009) Erin Madden et al.   AIDS

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial

(2009) Alexandra Calmy et al.   AIDS

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

(2009) Kimberly Y Smith et al.   AIDS

Relationship between Inflammatory Markers, Endothelial Activation Markers, and Carotid Intima‐Media Thickness in HIV‐Infected Patients Receiving Antiretroviral Therapy

(2009) Allison C. Ross et al.   CLINICAL INFECTIOUS DISEASES

Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy

(2008) Judith S. Currier et al.   CIRCULATION

No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavir‐Ritonavir in Healthy Subjects without HIV Infection: A Placebo‐Controlled Trial

(2008) Michael P. Dubé et al.   CLINICAL INFECTIOUS DISEASES

Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels

(2008) Jason S Reingold et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES